Autoimmunization for the prevention of HIV Infection
We have developed a novel immunopeptide that generates a sustained antibody response that inhibits HIV infection, without causing an autoimmune response.
Our composition of matter patent describes a biopharmaceutical technology that inhibits HIV cell entry via blocking of CCR5. This technology was invented by Prof Benny Chain, Head of the Division of Infection & immunity at UCL
Our pre-clinical data strongly supports the continuation of the pre-clinical programme we are undertaking, and we plan to enter a Phase 1 study shortly.
| Date added | 07 Dec 2009 |
|---|---|
| Reference number | 15-021 |
| Status | Patent application submitted on 29th September 2009 (No. 0917090.3). |
| Availability | Available for exclusive licensing |
| References | http://www.ucl.ac.uk/infection-immunity/themes/tumour |
The technology and its advantages
Current vaccines against HIV do not work, largely because the virus is extremely variable. An alternative approach is to block viral entry, by targeting the human receptor (CCR5) which is essential for the first steps of infection.
Targeting self receptors can be difficult, because the immune response tries to avoid reacting against “self”. It can also be hazardous, since the autoimmune response can damage the host.
Our patented technology generates an antibody response to one selected section of the CCR5 receptor, but induces no cellular immune response to the protein. Data to date indicates that functional antibodies are generated, and bind to CCR5 protein. It is well known in the field that inhibition of CCR5 is a viable strategy for impeding HIV infection.
Market opportunity
HIV continues to be one of the worlds leading heath concerns.
Further information
Please contact Chris Loryman, UCL Business PLC
T +44 (0)20 7679 9000
E c.loryman@uclb.com
